Thromboembolism

Prophylaxis With Apixaban Feasible for Cancer Patients

Primary venous thromboembolism prophylaxis with apixaban, an oral direct Factor Xa inhibitor, in ambulatory cancer patients undergoing first- or second-line chemotherapy for advanced or metastatic cancer, is safe and well tolerated, according to a Phase 2 study.

Next post in Side Effect Management